Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.58 |
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | GZMB | P10144 | 1/20 | 0.41 |
| ▸ | AADAT | Q8N5Z0 | 5/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197902 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL5669628 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL12893385 | 1.00 | ACE (0.58) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL10331861 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL7278473 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL7278480 | 0.92 | ACE (0.49) | ACEACE2MME | |
| SCHEMBL16804559 | 0.87 | ACE (0.47) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL7497338 | 0.85 | ACE (0.49) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL27015282 | 0.84 | ACE (0.61) | ACEACE2MMESTAT3GZMB | |
| SCHEMBL14169787 | 0.82 | ACE (0.45) | ACEACE2MMESTAT3GZMB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11698375-B2 | Method for producing an examination reagent and kit for analysing a T-cell frequency | CONSTRUCTOR UNIVERSITY BREMEN GGMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| WO-2023087871-A1 | GRANZYME B TARGETING COMPLEX, RADIOPHARMACEUTICAL, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京大学 | 2023-05-25 | — | — | WO | disclosed |
| US-20190331681-A1 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10386367-B2 | Method for producing an examination reagent and kit for analysing a T-cell frequency | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20140370524-A1 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2010118309-A2 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | ACE 167/4885ACE2 245/4885MME 28/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | ACE 3012/4885ACE2 2991/4885MME 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.